ArriVent BioPharma, Inc. Common Stock (AVBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) has a cash flow conversion efficiency ratio of -0.108x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.58 Million) by net assets ($366.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ArriVent BioPharma, Inc. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
ArriVent BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ArriVent BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ArriVent BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency. See AVBP cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
-0.849x |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
0.019x |
|
Wolverine World Wide Inc
NYSE:WWW
|
-0.192x |
|
Arlo Technologies
NYSE:ARLO
|
0.072x |
|
Varroc Engineering Limited
NSE:VARROC
|
0.199x |
|
VA Tech Wabag Limited
NSE:WABAG
|
-0.021x |
|
Orezone Gold Corporation
AU:ORE
|
0.302x |
|
Castellana Properties Socimi
MC:YCPS
|
0.041x |
Annual Cash Flow Conversion Efficiency for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. View ArriVent BioPharma, Inc. Common Stock (AVBP) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $307.22 Million | $-160.59 Million | -0.523x | -91.82% |
| 2024-09-30 | $257.65 Million | $-70.21 Million | -0.273x | +26.17% |
| 2023-09-30 | $151.30 Million | $-55.84 Million | -0.369x | -47.58% |
| 2022-09-30 | $174.46 Million | $-43.63 Million | -0.250x | +18.10% |
| 2021-09-30 | $41.22 Million | $-12.59 Million | -0.305x | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more